A phase II study of orally administered RO4929097, a gamma-secretase inhibitor, as a single agent in patients with recurrent or refractory Non-Small Cell Lung Cancer (NSCLC)

Update Il y a 4 ans
Reference: EUCTR2008-006384-37

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the effect of RO4929097 on tumor blood flow and tumor metabolic activity.


Inclusion criteria

  • Patients with recurrent or refractory stage IIIB/IV NSCLC

Links